MedTech Atlas
Back to medical device regulatory guideAll countries
Asia PacificENPublic regulatory overview

Thailand

Country Overview Market Notes: Thailand requires a locally licensed importer/license holder to serve as the registration applicant and import license holder. Local execution qualit...

Updated: 2026-05-04

You are viewing the public excerpt. During the limited-time free period, sign in to view the complete country report.

Sign in / register for full country report
Reference approval strategy

FDA / CE / MDSAP / NMPA benefits for this market

These factors can reduce evidence-building work, support review confidence, or shape the filing strategy. They do not automatically replace local registration.

US FDA

510(k) / De Novo / PMAModerate benefit

FDA evidence is useful technical and clinical support, but the local authority still performs an independent review.

Likely benefit
  • Use FDA review summaries, clearance or approval letters, test reports, clinical evidence, and software or electrical-safety files as support.
  • May reduce technical questions when the intended use, model scope, and evidence package match the local filing.
Limit
  • Does not remove local holder, language, labeling, fee, import, or post-market obligations.
View topic

EU CE

MDR / IVDRStrong benefit

CE documentation is highly reusable and may support reference, reliance, or overseas conformity assessment routes.

Likely benefit
  • Reuse MDR/IVDR technical documentation, clinical evaluation, ISO testing, GSPR or essential-principles mapping, labeling, and PMS evidence.
  • Often helps build CSDT, IMDRF, or local-format technical files faster.
Limit
  • Does not replace local registration or local representative responsibilities outside the CE-recognized route.
View topic

MDSAP

Single QMS auditIndirect QMS signal

MDSAP mainly supports ISO 13485/QMS maturity and does not reduce product review directly.

Likely benefit
  • Reduce duplicate quality-system audits and support ISO 13485, CAPA, complaints, supplier controls, design controls, and production controls.
  • Most useful when the market accepts MDSAP directly or when the application depends on QMS maturity.
Limit
  • Does not authorize product sale and does not replace safety, performance, or clinical evidence.
View topic

China NMPA

China registration / filingSupportive evidence

NMPA approval can serve as prior-market evidence and a commercial credibility signal, especially for China-made products.

Likely benefit
  • Use NMPA approval as prior-registration evidence, China market history, and product-maturity support.
  • Convert ISO/IEC-aligned testing, clinical, risk-management, and PMS documents from the NMPA file into the local dossier.
Limit
  • Do not assume automatic recognition; China-only GB/YY evidence may need retesting or restructuring.
View topic

AI Citation Summary

  • Country: Thailand
  • Product line: Medical devices
  • Regulator / source: Local licence holder - Who holds importer / licence-holder status? - Partner selection must cover regulatory filing, import licence, hospital channel, and service capability
  • Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
  • Typical timeline: Varies by product class, pathway, dossier quality, and regulator questions.
  • Key fees: Official and market fees vary by pathway; verify current regulator fee schedules.
  • Local requirement: Market Notes: Thailand requires a locally licensed importer/license holder to serve as the registration applicant and import license holder. Local execution quality, Thai-language labeling, and dossier compliance with TFDA (Thai FDA) format requirements are critical success factors for market entry.
  • Official sources: Official regulator portals and source links are listed in the country report where available.
  • Last verified: 2026-05-04
  • Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
  • Preferred citation: MedTech Atlas

Country Overview

  • Market Notes: Thailand requires a locally licensed importer/license holder to serve as the registration applicant and import license holder. Local execution quality, Thai-language labeling, and dossier compliance with TFDA (Thai FDA) format requirements are critical success factors for market entry.

Market-Entry Logic

Thailand medical-device entry should be separated into Thai FDA product classification, local importer / licence holder, import licence, technical dossier submission, Thai-language labelling, hospital procurement, and after-sales service. Foreign manufacturers usually cannot commercialise only from headquarters; a Thai licensed entity executes registration, importation, customs clearance, labelling, complaints, recalls, and hospital communication.

Entry layer Key question Practical view
Local licence holder Who holds importer / licence-holder status? Partner selection must cover regulatory filing, import licence, hospital channel, and service capability
Classification and pathway Class 1/2/3/4, IVD status, exemption or simplified requirement? Higher classes carry heavier dossier, clinical / performance evidence, and deficiency risk
Dossier and labelling Can CE / FDA files be converted into Thai FDA format, and is Thai labelling ready? CE / FDA evidence is useful, but it does not waive Thai labelling, importer information, or local registration-number requirements
Public channel Will the product enter public hospitals, MOH / procurement, or tenders? Public access depends on registration, importer authorisation, price, supply, and local service capability
Private channel Can BDMS, Bumrungrad, Samitivej, or other private hospitals drive adoption? Premium devices, IVD, cardiovascular, orthopaedics, imaging, and minimally invasive products often start in private demonstration sites

Main Players and Channel Map

Type Representative players Market meaning
Regulator Thai FDA, Ministry of Public Health Determine device classification, registration, import, labelling, and post-market regulation
Local importer / distributor Licensed importers, medical-device distributors, and service partners Execute registration, import, customs clearance, warehousing, tenders, installation, service, and recalls
Public healthcare MOH hospitals, regional public hospitals, and public procurement ecosystem High requirements for registration certificate, importer authorisation, pricing, supply, and service
Private healthcare BDMS / Bangkok Hospital, Bumrungrad, Samitivej, Bangkok Chain Hospital Concentrated demand for premium devices, diagnostics, imaging, minimally invasive products, and medical tourism
Commercialisation services DKSH Healthcare Thailand, Zuellig Pharma, and local device channel partners Support channel coverage, logistics, hospital relationships, tender execution, and service coordination
  1. Local importer / licence holder is central: Thailand's registration, import, labelling, and service duties depend heavily on the local licensed entity.
  2. Thai labelling and local registration-number requirements cannot wait: Label content, importer information, and Thai registration number often become late-stage blockers.
  3. CE / FDA evidence helps technically and commercially: Foreign certificates can reduce queries and improve hospital/importer confidence, but they are not an automatic expedited pathway.
  4. Private hospitals lead high-value device adoption: Medical tourism and premium private hospitals are useful first-adoption sites for innovative devices, IVDs, cardiovascular, orthopaedics, imaging, and minimally invasive products.
  5. Public procurement still depends on price and service: Public-market scale requires registration, price strategy, supply stability, and local service network.

Regulatory Authority

  • Primary Authority: Thai FDA (Food and Drug Administration, Thailand — อย.); operates under the Ministry of Public Health
  • Legal Framework: Medical Device Act B.E. 2562 (2019) and associated notifications and guidelines

Device Classification System

Local Class Risk Level Approximate EU Equivalent Notes
Class 1 Low Class I Lowest risk; simplified registration
Class 2 Low-Moderate Class IIa Standard registration; moderate documentation required
Class 3 Moderate-High Class IIb Full technical review required
Class 4 High Class III Most stringent; full clinical evidence requirements

Registration Pathways

During the limited-time free period, sign in or register to view the complete medical device country report.